引文於 訪客 在 2022-11-07, 03:06
Summary In summary, at least further 4 years of aromatase inhibitor treatment after the first 5 years of adjuvant tamoxifen is recommended in postmenopausal endocrine responsive early breast cancer, nowadays nolva tamoxifen
Summary In summary, at least further 4 years of aromatase inhibitor treatment after the first 5 years of adjuvant tamoxifen is recommended in postmenopausal endocrine responsive early breast cancer, nowadays nolva tamoxifen
